Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Payables (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Payables for 13 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Payables rose 14.54% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, up 14.54% year-over-year, with the annual reading at $2.6 million for FY2025, 14.54% up from the prior year.
  • Payables for Q4 2025 was $2.6 million at Theravance Biopharma, up from $2.2 million in the prior quarter.
  • The five-year high for Payables was $10.7 million in Q2 2021, with the low at $1.5 million in Q3 2024.
  • Average Payables over 5 years is $3.3 million, with a median of $2.3 million recorded in 2023.
  • The sharpest move saw Payables plummeted 77.9% in 2022, then soared 76.36% in 2023.
  • Over 5 years, Payables stood at $3.1 million in 2021, then plummeted by 49.84% to $1.6 million in 2022, then decreased by 1.93% to $1.5 million in 2023, then surged by 47.11% to $2.2 million in 2024, then grew by 14.54% to $2.6 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $2.6 million, $2.2 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.